AI precision pipeline
Drug and diagnostic pipeline
Our precision pipeline will deliver the right treatment to the right patient
Drug R&D
Indication
Solid tumors
Mesothelioma
Bladder cancer
DLBCL
Ovarian cancer
Early discovery
Pre-clinical
Phase I
Phase II
OKN4395
AI Diagnostics
Indication
Colorectral cancer
Colorectral cancer
Breast cancer
Pan-cancer
Breast cancer
Lung cancer
Endometrial cancer
Gastric cancer
Cholangiocarcinoma
Small intestine cancer
Proof of Concept
Development
Regulatory approval
Approved
MSIntuit® CRC V1
CE:
MSIntuit® CRC V2
Beta:
RlapsRisk® BC
RUO:
Beta:
TLS Detect Pan-cancer
RUO:
MSIntuit® EC - in collaboration with MSD
MSIntuit® GC - in collaboration with MSD
MSIntuit® CC - in collaboration with MSD
MSIntuit® SIC - in collaboration with MSD
Flags denote countries in which the AI Diagnostic is available.
What makes our pipeline different?
Powered by multimodal patient data, our AI models match novel targets with patient subgroups to identify the best treatments.
We merge wet lab experiments with advanced AI techniques to create a powerful feedback loop for accelerated discovery and innovation.